(Q38174652)

30 August 2017

Therapy of ocular Behçet disease (English)

1 reference

30 August 2017

0 references

Bahram Bodaghi

3

0 references

author name string

Manfred Zierhut

series ordinal

1

1 reference

30 August 2017

Ahmet M Abu El-Asrar

series ordinal

2

1 reference

30 August 2017

Ilknur Tugal-Tutkun

series ordinal

4

1 reference

30 August 2017

30 December 2013

1 reference

Ocular Immunology and Inflammation

30 August 2017

1 reference

30 August 2017

22

1 reference

30 August 2017

1

1 reference

30 August 2017

64-76

1 reference

Novel approaches to Behçet's disease

30 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Ocular features of Behcet's disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Fluorescein angiography and visual acuity in active uveitis with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

EULAR recommendations for the management of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Behçet's disease: ocular effects and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

A double-blind trial of colchicine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Azathioprine in Behcet's syndrome: effects on long-term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Azathioprine in severe uveitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Calcineurin inhibitors in renal transplantation: what is the best option?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Mycophenolate mofetil for the treatment of uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Short-term chlorambucil for refractory uveitis in Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

CXC chemokine expression profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Neovascularization of the optic disc in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Interferon-alpha-associated presumed ocular sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Vision- and health-related quality of life in patients with Behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Behçet's disease as an autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

The emerging role of interleukin-1β in autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Biologic drugs in autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Treatment of retinal vasculitis in Behçet's disease with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Registries in rheumatological and musculoskeletal conditions. Paediatric Behçet's disease: an international cohort study of 110 patients. One-year follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Childhood-onset uveitis in Behçet disease:a descriptive study of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Ocular findings in childhood-onset Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Uveitis associated with pediatric behçet disease in the american midwest

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Clinical and demographic evaluation of Behçet disease among different paediatric age groups

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Behçet disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Biological response modifier therapy for refractory childhood uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Intravitreal bevacizumab (Avastin) for the treatment of cystoid macular edema in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Intravitreal bevacizumab treatment of macular edema due to optic disc vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Male sex, erythema nodosum, and electroretinography as predictors of visual prognosis after cataract surgery in patients with Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Clinical Course before and after Cataract and Glaucoma Surgery under Systemic Infliximab Therapy in Patients with Behçet's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Cataract Surgery in Behçet's Disease Patients One Week after Infliximab Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09273948.2013.866257

10.3109/09273948.2013.866257

21 January 2018

Identifiers

DOI

1 reference

release_3aud53m5zrcovb6cmvjdu4yi64

30 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3aud53m5zrcovb6cmvjdu4yi64

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference